Imfinzi (durvalumab) - AstraZeneca
Imjudo (tremelimumab-actl) - AstraZeneca
Yervoy (ipilimumab) - BMS
AiTan (rivoceranib) - Elevar Therapeutics
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
sorafenib - Generic mfg.
Anniko (penpulimab-kcqx) - Akesobio, Sino Biopharm
Lenvima (lenvatinib) - Eisai, Merck (MSD)
Avastin (bevacizumab) - Roche
Keytruda (pembrolizumab) - Merck (MSD)
Cabometyx (cabozantinib tablet) - Exelixis
Focus V (anlotinib) - Advenchen
AiRuiKa (camrelizumab) - Elevar Therapeutics
Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology
http://www.ncbi.nlm.nih.gov/pubmed/42707851
 
Andrea Messori; Andrea Ossato; Elena Orlandi; Lorenzo Gasperoni; Luna Del Bono; Stefano Vecchia; Vera Damuzzo
 
Sep 9, 2026
 
Prev Next